ChatGPT 100,000 Patient 24-Month *In Silico* Phase III 5-Arm Pancreatic Cancer Clinical Trial Triplicate

Kevin Kawchak
Chief Executive Officer
ChemicalQDevice
San Diego, CA
July 24, 2025
kevink@chemicalqdevice.com

19.S43.DAT.02.TAB

Contents:

"Trial 1: Table 5-1 Start"

Table 5-1. Baseline Characteristics by Arm (N=20,000 per arm).

Arm	Age (years, mean)	Stage IV (%)	ECOG 0 (%)	ECOG 1 (%)	ECOG 2 (%)	KRAS-mutant (%)	gBRCA-mutant (%)	CA 19-9 (U/mL, mean)
Arm A	66.2	88.0	20.0	74.2	5.8	91.1	5.0	5,854
Arm B	66.2	88.0	20.0	74.0	6.0	90.9	5.0	5,848

Arm C	66.3	87.9	19.6	74.4	6.0	90.8	5.0	5,863
Arm D	66.4	88.1	20.1	73.9	6.0	90.9	5.0	5,849
Arm E	66.2	87.9	20.0	74.3	5.8	91.1	5.0	5,875

Abbreviations: ECOG = Eastern Cooperative Oncology Group performance status; KRAS-mutant = any KRAS mutation (including G12C); gBRCA-mutant = germline BRCA1/2 mutation; CA 19-9 = carbohydrate antigen 19-9 tumor marker.

“Trial 1: Table 5-1 End”

“Trial 2: Table 5-1 Start”

Table 5-1. Baseline Characteristics by Arm.

Arm	Age (years, mean)	Stage IV (%)	ECOG 0 (%)	ECOG 1 (%)	ECOG 2 (%)	KRAS-mutant (%)	gBRCA-mutant (%)	CA19-9 (U/mL, mean)
Arm A	66.3	88.3	19.9	74.0	6.1	91.2	5.0	5869.8
Arm B	66.2	87.9	20.0	74.2	5.8	90.7	5.0	5803.2

Arm C	66.4	88.1	20.5	73.6	5.9	90.8	5.0	5853.2
Arm D	66.4	87.8	20.4	73.4	6.2	91.0	5.0	5816.2
Arm E	66.3	87.8	20.0	74.1	5.9	90.7	5.0	5856.0

“Trial 2: Table 5-1 End”

“Trial 3: Table 5-1 Start”

Table 5-1: Baseline Characteristics by Arm. Each value is a mean or percentage for the given arm (N=20,000 per arm). All arms were well balanced with respect to demographics and disease features.

Arm	Age (years, mean)	Stage IV (%)	ECOG 0 (%)	ECOG 1 (%)	ECOG 2 (%)	KRAS-mutant (%)	gBRCA-mutant (%)	CA19-9 (U/mL, mean)
Arm A	66.4	88.1	20.4	73.5	6.1	90.9	5.0	5830.8
Arm B	66.3	87.8	19.8	74.1	6.1	90.9	5.0	5774.0
Arm C	66.3	88.0	20.2	73.9	6.0	90.8	5.0	5842.1

Arm D	66.2	88.1	19.6	74.5	5.9	91.0	5.0	5816.4
Arm E	66.2	87.9	20.0	74.1	5.9	90.9	5.0	5882.9

“Trial 3: Table 5-1 End”

“Trial 1: Table 6-1 Start”

Table 6-1. Primary Efficacy Outcomes by Arm (24-month KM analysis).

Arm	Median PFS (mo)	Median OS (mo)	12-month OS Rate (%)	PFS HR vs Control	OS HR vs Control
Arm A (Triplet D+M+I)	4.5 mo	8.7 mo	38.7%	0.68	0.69
Arm B (Doublet M+I)	3.3 mo	6.8 mo	29.6%	0.93	0.90
Arm C (Doublet D+I)	3.9 mo	7.3 mo	32.1%	0.78	0.84

Arm D (Doublet D+M)	4.1 mo	8.1 mo	35.9%	0.74	0.75
Arm E (Control chemo)	3.0 mo	6.1 mo	25.5%	1.00	1.00

Notes: Medians and rates are from Kaplan-Meier estimates (all data censored at 24 months). Hazard ratios (HR) < 1 favor the combination arms. D = Daraxonrasib; M = Mitazalimab; I = liposomal Irinotecan.

“Trial 1: Table 6-1 End”

“Trial 2: Table 6-1 Start”

Table 6-1. Primary Efficacy Outcomes by Arm.

Arm	Median PFS (mo)	Median OS (mo)	12-month OS Rate (%)	PFS HR vs Control	OS HR vs Control
Arm A	4.5	8.7	38.4	0.68	0.69
Arm B	3.2	6.8	29.9	0.93	0.89
Arm C	3.9	7.2	32.2	0.78	0.84
Arm D	4.1	8.0	35.4	0.75	0.76

Arm E	3.0	6.2	25.5	1.00	1.00

“Trial 2: Table 6-1 End”

“Trial 3: Table 6-1 Start”

Table 6-1: Primary Efficacy Outcomes by Arm. Efficacy endpoints were analyzed by Kaplan-Meier method (24-month maximum follow-up). Hazard ratios (HR) are computed for each experimental arm vs. control (Arm E).

Arm	Median PFS (mo)	Median OS (mo)	12-month OS Rate (%)	PFS HR vs Control	OS HR vs Control
Arm A	4.6	8.8	38.8	0.68	0.70
Arm B	3.2	6.8	29.7	0.97	0.90
Arm C	3.9	7.2	31.5	0.80	0.85
Arm D	4.2	8.1	34.9	0.75	0.76
Arm E	3.1	6.1	25.1	1.00	1.00

“Trial 3: Table 6-1 End”

“Trial 1: Table 7-1 Start”

Table 7-1. Incidence of Grade ≥3 Adverse Events by Arm (0–24 months).

Arm	Patients with ≥G3 AE (%)
Arm A (Triplet D+M+I)	94.2%
Arm B (Doublet M+I)	88.8%
Arm C (Doublet D+I)	85.0%
Arm D (Doublet D+M)	80.9%
Arm E (Control nal-IRI)	76.5%

“Trial 1: Table 7-1 End”

“Trial 2: Table 7-1 Start”

Table 7-1. Global Safety Summary by Arm.

Arm	Any ≥G3 AE (%)
Arm A	94.3
Arm B	88.9
Arm C	84.7
Arm D	80.6
Arm E	76.5

“Trial 2: Table 7-1 End”

“Trial 3: Table 7-1 Start”

Table 7-1: Global Safety Summary by Arm. Percentage of patients who experienced any Grade ≥3 adverse event within 24 months of follow-up (cumulative incidence).

Arm	Any ≥G3 AE (%)

Arm A	94.6
Arm B	88.4
Arm C	86.1
Arm D	81.6
Arm E	76.5

“Trial 3: Table 7-1 End”

“Trial 1: Table 8-1 Start”

Table 8-1. Median PFS (months) by Patient Archetype and Treatment Arm.

Archetype (ID)	Arm A (Triplet)	Arm B (M+I)	Arm C (D+I)	Arm D (D+M)	Arm E (Control)
ARCH-01 (Young_Fit_Metastatic)	4.5 mo	3.3 mo	3.9 mo	4.4 mo	3.0 mo

ARCH-02 (Elderly_Frail_Metastatic)	4.7 mo	3.3 mo	4.1 mo	4.0 mo	3.0 mo
ARCH-03 (LAPC_Standard_Fitness)	4.6 mo	3.3 mo	4.0 mo	4.2 mo	2.8 mo
ARCH-04 (Young_Fit_BRCAm)	4.3 mo	3.1 mo	4.0 mo	4.1 mo	3.2 mo
ARCH-05 (Metastatic_KRAS_G12C)	4.4 mo	3.7 mo	3.7 mo	4.3 mo	3.1 mo
ARCH-06 (Metastatic_High_Stroma)	4.6 mo	3.1 mo	3.7 mo	3.9 mo	3.0 mo
ARCH-07 (Advanced_Refractory_PS1)	4.5 mo	3.3 mo	3.9 mo	4.1 mo	3.1 mo

“Trial 1: Table 8-1 End”

“Trial 2: Table 8-1 Start”

Table 8-1. Median PFS (months) by Archetype and Arm.

Archetype	Arm A	Arm B	Arm C	Arm D	Arm E

ARCH-01	4.6	3.3	3.9	4.1	3.1
ARCH-02	4.5	3.1	4.0	4.1	3.1
ARCH-03	4.5	3.3	3.7	4.5	2.9
ARCH-04	4.5	3.4	4.0	4.1	3.1
ARCH-05	4.5	3.2	4.0	4.1	3.0
ARCH-06	4.7	3.3	4.1	4.1	3.0
ARCH-07	4.5	3.3	3.9	4.1	3.0

“Trial 2: Table 8-1 End”

“Trial 3: Table 8-1 Start”

Table 8-1: Median PFS (months) by Archetype and Arm. Subgroup analysis of progression-free survival. Each cell is the median PFS in months for the given subgroup (row) and treatment arm (column).

Archetype	Arm A	Arm B	Arm C	Arm D	Arm E

ARCH-01 – Young_Fit_Metastatic	4.6	3.2	3.8	4.3	3.1
ARCH-02 – Elderly_Frail_Metastatic	4.0	2.9	3.3	3.7	2.8
ARCH-03 – LAPC_Standard_Fitness	5.7	4.1	4.6	5.3	4.0
ARCH-04 – Young_Fit_BRCAm	4.6	3.3	3.7	4.2	3.0
ARCH-05 – Metastatic_KRAS_G12C	4.9	3.1	4.2	3.9	3.1
ARCH-06 – Metastatic_High_Stroma	4.5	3.1	3.8	4.2	3.1
ARCH-07 – Advanced_Refractory_PS1	4.1	3.0	3.5	3.8	2.9

“Trial 3: Table 8-1 End”

“Trial 1: Table 8-2 Start”

Table 8-2. Median OS (months) by Patient Archetype and Treatment Arm.

Archetype (ID)	Arm A (Triplet)	Arm B (M+I)	Arm C (D+I)	Arm D (D+M)	Arm E (Control)
ARCH-01 (Young_Fit_Metastatic)	8.9 mo	6.7 mo	7.1 mo	7.9 mo	6.2 mo
ARCH-02 (Elderly_Frail_Metastatic)	8.8 mo	6.9 mo	7.5 mo	7.7 mo	6.1 mo
ARCH-03 (LAPC_Standard_Fitness)	8.3 mo	6.9 mo	7.2 mo	8.5 mo	6.2 mo
ARCH-04 (Young_Fit_BRCAm)	8.0 mo	6.9 mo	7.0 mo	7.9 mo	5.6 mo
ARCH-05 (Metastatic_KRAS_G12C)	8.4 mo	7.0 mo	7.3 mo	8.3 mo	6.5 mo
ARCH-06 (Metastatic_High_Stroma)	8.8 mo	6.5 mo	7.1 mo	8.1 mo	6.2 mo
ARCH-07 (Advanced_Refractory_PS1)	8.7 mo	6.7 mo	7.3 mo	8.2 mo	6.2 mo

Note: Each archetype represents a distinct patient profile (see Section 2.1 for definitions). Median OS/PFS were calculated within each subgroup; all data are censored at 24 months.

“Trial 1: Table 8-2 End”

“Trial 2: Table 8-2 Start”

Table 8-2. Median OS (months) by Archetype and Arm.

Archetype	Arm A	Arm B	Arm C	Arm D	Arm E
ARCH-01	9.0	6.7	7.2	7.9	6.3
ARCH-02	8.4	6.7	7.1	8.2	6.1
ARCH-03	9.1	6.8	7.2	7.7	6.1
ARCH-04	8.9	6.6	7.2	7.9	6.3
ARCH-05	8.8	6.8	7.0	7.7	6.1
ARCH-06	8.7	6.9	7.4	7.5	6.0
ARCH-07	8.5	6.9	7.2	8.2	6.1

“Trial 2: Table 8-2 End”

“Trial 3: Table 8-2 Start”

Table 8-2: Median OS (months) by Archetype and Arm. Subgroup analysis of overall survival.

Archetype	Arm A	Arm B	Arm C	Arm D	Arm E
ARCH-01 – Young_Fit_Metastatic	8.8	6.9	7.4	8.1	6.2
ARCH-02 – Elderly_Frail_Metastatic	8.0	5.7	6.4	7.0	5.6
ARCH-03 – LAPC_Standard_Fitness	10.3	7.4	8.0	9.3	7.2
ARCH-04 – Young_Fit_BRCAm	8.6	6.7	7.4	7.9	6.1
ARCH-05 – Metastatic_KRAS_G12C	8.8	6.3	7.1	8.6	6.2
ARCH-06 – Metastatic_High_Stroma	8.8	6.5	7.2	8.1	6.2
ARCH-07 – Advanced_Refractory_PS1	8.0	6.0	6.6	7.4	5.8

“Trial 3: Table 8-2 End”